Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diltiazem in new kidney transplant recipients receiving tacrolimus
TCTR20260911006Active, not recruiting
- Sponsor
- Health Systems Research Institute
- Start
- Jun 2026
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Open-label trial of diltiazem and tacrolimus in kidney failure (2 arms), sponsored by Health Systems Research Institute. Primary endpoint: Acute rejection. Started Jun 2026; status: active, not recruiting.
02
Drugs
diltiazemtacrolimus
03
Conditions
kidney failure
Beyond the preview
Go deeper on TCTR20260911006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260911006.